STAT+: New data on Eli Lilly’s ‘triple-G’ drug leave open questions on heart benefit — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Eli Lilly reported Phase 3 results Thursday showing that patients on the highest dose of retatrutide lost 22.6% of body weight after 80 weeks, compared with 3.2% for placebo, among participants who stayed on treatment.
- The retatrutide trial enrolled nearly 2,000 people with severe obesity and heart disease, with or without diabetes.
- On secondary cardiovascular endpoints measuring death, heart attack, or stroke, retatrutide patients did not achieve a statistically significant lower risk of major events than placebo.
- Lilly said the trial was not powered to study cardiovascular outcomes and noted that fewer heart events occurred than anticipated.
Why it matters: With a 22.6% weight-loss result among nearly 2,000 patients with heart disease, Lilly had positioned this trial to deliver both an efficacy and a cardiovascular signal. The missing statistical significance on secondary CV endpoints, combined with fewer heart events than expected, means whether retatrutide reduces cardiovascular risk remains unanswered by this study alone.
Ask SkimNews
